Pharma & Biotech

IMAC Holdings is undergoing a significant corporate transformation, fundamentally shifting its core business model. The company is moving away from...

The primary objective for 22nd Century Group remains clear: reaching profitability by 2026. The company is intensifying efforts to scale...

Investors in Stoke Therapeutics are monitoring a series of imminent catalysts as the company advances its clinical pipeline. The coming...

Bio Green Med Solution, Inc., the post-restructuring entity formerly known as Cyclacel Pharmaceuticals, has entered a measured, quiet phase as...

The Chapter 7 proceedings for Athersys, the developer behind MultiStem, are entering their tail end in a U.S. bankruptcy court...

BridgeBio Pharma announced yesterday the successful completion of the pivotal Phase 3 PROPEL 3 study evaluating Infigratinib. The data demonstrate...

Atreca, the biotechnology firm, is in the final phase of its wind-down and formal dissolution. Shareholders had already endorsed this...

Investors holding shares of Novan have reached the end of the line. The company's stock is now effectively worthless, a...

Biotechnology firm Rallybio is navigating a significant operational transition. Having recently adjusted its capital structure to secure its stock exchange...

While Eli Lilly continues to generate headlines and record earnings with its blockbuster weight-loss drugs, the pharmaceutical giant's leadership is...